SCHEDULE 2Transitionals and savings
Part 15Research and development
Qualifying expenditure on relevant payments to subjects of clinical trials
124
(1)
In relation to expenditure incurred before 1 August 2008, Chapter 2 of Part 13 (relief for SMEs: cost of R&D borne by SME) applies with the omission of—
(a)
section 1052(2)(d),
(b)
section 1071(3)(d),
(c)
in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and
(d)
section 1140, as it applies for the purposes of that Chapter.
(2)
In relation to expenditure incurred before 1 August 2008, Chapter 3 of Part 13 (relief for SMEs: cost of R&D sub-contracted to SME) applies with the omission of—
(a)
section 1066(3)(d), and
(b)
section 1140, as it applies for the purposes of that Chapter.
(3)
In relation to expenditure incurred before 1 April 2006, Chapter 4 of Part 13 (relief for SMEs: subsidised expenditure on R&D) applies with the omission of—
(a)
section 1071(3)(d),
(b)
in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and
(c)
section 1140, as it applies for the purposes of that Chapter.
(4)
In relation to expenditure incurred before 1 April 2006, Chapter 5 of Part 13 (relief for large companies) applies with the omission of—
(a)
section 1077(2)(d), and
(b)
section 1140, as it applies for the purposes of that Chapter.
(5)
In relation to expenditure incurred before 1 August 2008, Chapter 7 of Part 13 (relief for SMEs and large companies: vaccine research etc) applies with the omission of—
(a)
section 1101(4)(d), and
(b)
section 1140, as it applies for the purposes of that Chapter.